首页 | 本学科首页   官方微博 | 高级检索  
检索        

骨髓树突状细胞融合瘤苗抗肿瘤免疫预防与治疗的实验研究
引用本文:董子明,张义国,杨洪艳,赵明耀,郑智敏.骨髓树突状细胞融合瘤苗抗肿瘤免疫预防与治疗的实验研究[J].郑州大学学报(医学版),1999(1).
作者姓名:董子明  张义国  杨洪艳  赵明耀  郑智敏
作者单位:河南医科大学病理病理生理学教研室
基金项目:河南医科大学回国人员科研启动基金,河南医科大学基础医学院科研基金,河南省教委重点攻关项目,河南省科委重点攻关项目
摘    要:目的:进一步研究树突状细胞与肿瘤细胞的融合瘤苗细胞主动免疫诱导体内抗肿瘤免疫反应及对荷瘤小鼠的免疫治疗效果。方法:直接分离骨髓树突状细胞和体外生长因子诱导扩增培养相结合,获得大量高纯度的树突状细胞,再以500g/LPEG诱导其与NS1骨髓细胞融合,HAT选择培养得到两者的融合细胞,体外进行混合淋巴细胞培养,并进行免疫预防与治疗的在体动物实验。结果:融合细胞也能诱导淋巴细胞的增殖反应,而NS1无此作用。体内免疫预防试验表明,融合细胞活瘤苗1次免疫后,诱导出较强的细胞毒性T淋巴细胞(CTL),并获得抵抗野生型NS1攻击的保护性反应,但对无关瘤株则无此抵抗力。融合细胞对荷瘤小鼠的免疫治疗试验显示,融合细胞静脉注射后,能够明显抑制肿瘤生长,延长其生存期。结论:树突状细胞与肿瘤细胞融合后的瘤苗体内免疫,能有效地诱导抗肿瘤免疫反应,可望成为肿瘤免疫预防和免疫治疗的新途径。

关 键 词:树突状细胞  细胞融合  肿瘤疫苗  免疫接种  免疫预防  免疫治疗  荷瘤  骨髓瘤  小鼠

Induced antitumor immunopreventive and immunotherapeutic effects in mice by the fusion cancer vaccine of bone marrow derived dendritic cells and NS 1 myeloma cells
Dong Ziming,Zhang Yiguo,Yang Hongyan,Zhao Mingyao,Zheng Zhimin.Induced antitumor immunopreventive and immunotherapeutic effects in mice by the fusion cancer vaccine of bone marrow derived dendritic cells and NS 1 myeloma cells[J].Journal of Zhengzhou University: Med Sci,1999(1).
Authors:Dong Ziming  Zhang Yiguo  Yang Hongyan  Zhao Mingyao  Zheng Zhimin
Institution:Dong Ziming,Zhang Yiguo,Yang Hongyan,Zhao Mingyao,Zheng Zhimin Department of Pathophysiology,Henan Medical University,Zhengzhou 450052
Abstract:Aims: Further to study in vivo induction of host antitumor immunoprotective responses actively immunized with fusion cells based cancer vaccine of dendritic cells (DC)and cancer cells and its immunotherapeutical effects on tumor bearing mice.Methods:A large number of bone marrow derived DCS with high purity were generated with a combination of fresh isolation and in vitro cytokines induced expansion procedures established in our laboratory,and then fused with NS 1 myeloma cells using 50% polyethylene glycol (PEG) fusion protocol.The fusion cells were selected by culturing in the presence of HAT and HT cytokines,and then intravenously injected into mice to investigate antitumor immune preventative and therapeutic effects.Results:The fusion cells could stimulate proliferation of mixed T lymphocytes in vitro,but NS 1 cells could not.Normal mice vaccinated with lively fused cells for the first time were induced to develop more potent cytotoxic T lymphocytes (CTL) activity against parental NS 1 cells,and led to the resistance specially against the challenge and rechallenge of wild live parental tumor cells for more than 90 days.After treatment with alive fusion cells,the surval time of tumor bearing mice was greatly extended and the tumor volume increased very slowly or did not,or even decreased compared to cnotrol mice.Conclusions:These results suggest that active immunization with the fusion cells of dendritic and tumor cells as a cancer vaccine could induce effectively antitumor inmmune responses,and that it is likely to become a new way of tumor prevention and treatment.
Keywords:dendritic cells  cell fusion  cancer vaccines  vaccination  immunoprevention  immunotherapy  tumor  bearing animal model  myeloma  mouse
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号